Infliximab in primary Sjögren's syndrome: One‐year followup
- 12 December 2002
- journal article
- retracted article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 46 (12) , 3301-3303
- https://doi.org/10.1002/art.10674
Abstract
Objective To evaluate the safety and efficacy of a maintenance regimen of infliximab in patients with active primary Sjögren's syndrome (SS) over a 1‐year period. Methods This followup study included 10 of the 16 patients with primary SS who participated in a pilot study. Patients who continued to have symptoms received additional infusions of infliximab for 1 year. Results All patients completed the 1‐year followup for evaluation of efficacy. After 1 year, a statistically significant decrease in global and local disease manifestations was observed in all 10 patients. Treatment was generally well tolerated, with the main side effect being a mild, self‐limited infusion reaction. Conclusion Sustained improvement of active primary SS may be possible with infliximab treatment.Funding Information
- Fund for Medical Scientific Research (FRSM), Belgium (3.4551.01)
This publication has 5 references indexed in Scilit:
- Infliximab in patients with primary Sjögren's syndrome: A pilot studyArthritis & Rheumatism, 2001
- Successful treatment of active ankylosing spondylitis with the anti–tumor necrosis factor α monoclonal antibody infliximabArthritis & Rheumatism, 2000
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European communityArthritis & Rheumatism, 1993
- Sjögren's syndrome. Proposed criteria for classificationArthritis & Rheumatism, 1986